Thermo Fisher Scientific Empowers Adolescents with Atopic Dermatitis
Thermo Fisher Scientific Empowers Adolescents with New Registry
Thermo Fisher Scientific Inc., renowned globally for its commitment to scientific progress, has recently made significant strides in addressing health challenges faced by adolescents. The newly launched international CorEvitas Adolescent Atopic Dermatitis (AD) Registry aims to tackle adolescent AD, which is a commonly occurring inflammatory skin condition.
Expanding Horizons: The Need for a Dedicated Registry
The CorEvitas registry marks an important moment as it welcomes the first patient from the European Union, broadening its previously North American-centric enrollment network. This expansion follows the first patient enrollment in late 2023 in North America. The registry is poised to fill crucial gaps in real-world evidence, particularly tailored to adolescent patients who require specific developmental and safety data linked to new AD therapies. It also works alongside the existing adult CorEvitas AD Registry, which was established in 2020.
Unpacking Atopic Dermatitis in Adolescents
Atopic Dermatitis, often referred to as pediatric eczema, is a chronic skin condition that predominantly affects children, typically surfacing between three and six months of age and possibly extending into adolescence. The prevalence of this condition varies globally, affecting approximately 10-30% of children. Even if symptoms appear to diminish during childhood, many may experience a resurgence of AD in their teenage years, highlighting the ongoing challenges posed by the condition.
The Psychological Impact of Atopic Dermatitis
The psychological effects of adolescent AD can be significant, leading to issues such as poor self-esteem and difficulties in social interactions. Jeffrey Greenberg, M.D., chief medical officer at CorEvitas, highlights that while the condition may not impede physical capabilities, the emotional strain can impact various aspects of life, including sleep, mood, and personal relationships. The new CorEvitas registry aims to enable comprehensive evaluations of adolescents with AD, providing valuable insights into the disease and treatment approaches that can significantly alleviate the sufferings associated with it.
Research Goals and Registry Data Collection
This registry is designed to collect extensive prospective data that will facilitate effective research into safety and efficacy. The specialized evaluation will also include a detailed examination of comorbid medical conditions and growth milestones in adolescent patients. Clinicians will document specific metrics, such as the percentage of body surface area affected and Atopic Dermatitis severity scores, while patients will provide feedback on their quality of life and symptom impact.
About CorEvitas and Patient-Centric Registries
CorEvitas specializes in proprietary registries that encompass autoimmune and inflammatory diseases, collecting structured, regulatory-grade clinical data from over 100,000 patients across 400 investigation sites. This independent registry model has gained acceptance from regulatory authorities for conducting long-term safety studies across diverse disease categories, confirming its reliability in longitudinal patient follow-ups.
Connecting with CorEvitas
For those seeking further information on this innovative registry and the study as a whole, interested parties can reach out through designated email addresses specifically created for U.S., Canada, and European inquiries.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. stands as the global frontrunner in scientific service provision, with annual revenues exceeding $40 billion. Their mission focuses on empowering customers to foster a healthier, cleaner, and safer world. Thermo Fisher's extensive product and service offerings support an array of sectors, including life sciences research, intricate analytical problem-solving, and diagnostics. Featuring esteemed brands, Thermo Fisher is dedicated to delivering unparalleled innovative solutions to their clients, ensuring their success in making impactful scientific advancements.
Frequently Asked Questions
What is the CorEvitas Adolescent Atopic Dermatitis Registry?
The registry is established to study new treatments and collect data specifically for adolescents suffering from Atopic Dermatitis.
Why is this registry important for adolescents?
The registry addresses an unmet need for real-world evidence and adolescent-specific data, aiding in the development of tailored therapies.
Who oversees the registry?
It is guided by prominent dermatology experts to ensure the scientific rigor of the data collected.
How does Atopic Dermatitis affect teenagers?
It can lead to psychological issues, influencing self-esteem and social interactions, particularly during adolescence.
What types of data will be collected in the registry?
The registry will gather comprehensive data on patient experiences, comorbid conditions, and treatment outcomes to better understand the effects of AD in adolescents.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Weave Dominates G2’s Fall Report with 21 Category Wins
- Davenforth Expands Managed IT Offerings with Key Acquisitions
- Golar MK II FLNG Project Advances with CIMC Raffles Partnership
- VEON Expands Leadership Team with New Executives in Dubai
- Celebrate Nokian Tyres' 90th with Special Rebate Offer
- EchoStar Corp's Strategic Move with DirecTV Affects Stock
- Parsons Achieves Key Milestone with NOAA’s TraCSS Program
- Kala Hanson's Excellence Acknowledged with Supply Chain Award
- Hitachi Astemo Celebrates 13 Years with Team Penske and Chevrolet
- Adyton Resources Advances with Major Private Placement Plans
Recent Articles
- Resilience Welcomes Dr. Susan Billings as Chief Commercial Officer
- Innovative Partnership Enhances Smart Metering Solutions
- Varian Partners with Sun Nuclear to Enhance QA Solutions
- Alfa Sustainable Projects Ltd. Leads Global Net Zero Certification
- Aethon United Completes Major Amendment to Credit Agreement
- Starboard Group Enhances Onboard Beauty with AI Skin Analysis
- FDA Grants Orphan Drug Designation to Navenibart for HAE
- Innovative 24/7 Pet Care Launches in Your Community
- Shoals Technologies Strengthens Leadership with New Appointments
- Stellantis Adjusts 2024 Outlook as Stock Faces Challenges
- Celebrating Innovation: o9 Reveals 2024 Partner Award Winners
- Biora Therapeutics Celebrates Recognition for Research at ACG 2024
- Market Anticipation Grows Ahead of Upcoming Jobs Report
- Celebrating Kerstin Woods as a 2024 Woman in Business Nominee
- Galectin Therapeutics Announces Attendance at MASH Conference
- Insights on Western Asset Inflation-Linked Income Fund's Distributions
- Ultralife Corporation's Strategic Move to Acquire Electrochem
- Western Asset Inflation-Linked Fund Distributions Announced
- Korro Bio Unveils Presentations at Oligonucleotide Therapy Event
- HarborOne Bancorp Announces Dividend for Third Quarter 2024
- AMN Healthcare Announces Upcoming Earnings Conference Call
- Pacific Premier Bancorp Prepares for Third Quarter Financial Review
- Plasma Fractionation Market Projected to Reach $63.27 Billion
- VICI Properties Inc. Plans Third Quarter 2024 Earnings Report
- Cortechs.ai Partners with Ascend Imaging for Radiology Growth
- Putnam Investments Outlines Latest Distribution Rates for Funds
- FMC Corporation Partners with Ballagro to Boost Crop Protection
- Transformative Changes Needed at AGCO for Future Success
- Neeve's $15 Million Funding Boosts Smart Building Innovation
- TransPerfect Expands Capabilities with Paybooks Technologies
- WNS and Uniqus Collaborate on Sustainable Accounting Solutions
- kdc/one Expands Cosmetics Packaging through Laffon Acquisition
- Schouw & Co. Announces Progress in Share Buy-Back Plan
- Canoo's Groundbreaking Oklahoma Plant: A New Era in EVs
- Seven Hills Realty Trust Announces Q3 2024 Earnings Call Details
- ResMed Launches Innovative CPAP Mask for Enhanced Sleep Therapy
- Electrosoft Secures Major Contract with DLA for IT Services
- Advent International Welcomes Carmine Di Sibio as New Leader
- Dovetail Genomics Unveils New Service Provider Program
- Inspire Agency Partners with Ritedose Corporation for Growth
- Wispr Secures $12M Investment to Revolutionize Voice Technology
- Palisades Nuclear Plant's Historic Restart and Its Future Impact
- Revolutionary sa-mRNA COVID-19 Vaccine Shows Lasting Effects
- AT&T Sells DirecTV Stake as Dish Network Merges with DirecTV
- Alliant Insurance Services Strengthens Community Ties through IICF
- Air Products Enhances Focus on Industrial Gases with Major Sale
- Le Balt Project: Revamping Urban Rental Living Experience
- Pathward Recognized for Innovative Banking Services Excellence
- Crombie REIT Expands Portfolio with Zephyr Acquisition Strategy
- Rising Consumer Expectations for Honesty in Marketing Practices